- 1 Enhanced Peer-Group strategies to support prevention of Mother-to-Child HIV
- 2 transmission leads to increased retention in care in Uganda: A Randomized controlled
- 3 trial

- 4 §Alexander Amone¹, §Grace Gabagaya¹, Priscilla Wavamunno¹, Gordon Rukundo¹, Joyce
- 5 Namale-Matovu¹, Samuel S. Malamba², Irene Lubega¹, Jaco Homsy³, Rachel King³,
- 6 Clemensia Nakabiito¹, Zikulah Namukwaya¹, Mary Glenn Fowler^{1,4} and Philippa Musoke^{1,5}
- 8 ¹ Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda
- 9 ² Uganda Virus Research Institute, Entebbe, Uganda
- ³ Institute for Global Health Sciences, University of California, San Francisco, CA, USA
- ⁴ Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD,
- 12 *USA*
- ⁵ Department of Pediatrics and Child Health, Makerere University College of Health Sciences,
- 14 Kampala, Uganda
- SCorresponding author: Alexander Amone, Makerere University Johns Hopkins University
- Research Collaboration, P.O. Box 23491, Kampala, Uganda; Tel/Fax: +256 200 404100 /
- +256 414 541044.
- 18 Email: <u>aamone@mujhu.org</u>
- 20 §These authors have contributed equally to the work.
- 21 Trial registration: ClinicalTrials.gov
- 22 Key words: HIV; Adherence; Peer support; Option B+; antiretroviral therapy; Retention in
- 23 care

19

24 Word count:

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Abstract: 352

26 Main text: 3571/3500

Abstract

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

Introduction: Despite scale up of Option B+, long-term retention of women in HIV care during pregnancy and the postpartum period remains an important challenge. We compared adherence to clinic appointments and antiretroviral therapy (ART) at different follow-up time points between enrolment and 24 months postpartum among pregnant women living with HIV and initiating Option B+ randomized to a peer group support, community-based drug distribution and income-generating intervention called "Friends for Life Circles" (FLCs) versus the standard of care (SOC). Methods: Between 16 May 2016 and 12 September 2017, 540 ART-naïve pregnant women living with HIV at urban and rural health facilities in Uganda were enrolled in the study. Participants were randomized 1:1 to the FLC intervention or SOC and assessed for adherence to prevention of mother to child HIV transmission (PMTCT) clinic appointments at 6 weeks, 12 and 24 months postpartum, self-reported adherence to ART at 6 weeks, 6 and 24 months postpartum validated by plasma HIV-1 RNA viral load (VL) measured at the same time points, and HIV status and HIV-free survival of infants at 18 months postpartum. We used Log-rank and Chi-Square p-values to test the equality of Kaplan-Meier survival probabilities and hazard rates (HR) for failure to retain in care for any reason by study arm. **Results:** There was no significant difference in adherence to PMTCT clinic visits or to ART or in median viral loads between FLC and SOC arms at any follow-up time points. Retention in care through the end of study was high in both arms but significantly higher among participants randomized to FLC (86.7%) compared to SOC (79.3%), p=0.022. The adjusted HR of visit dropout was 2.5 times greater among participants randomized to SOC compared to FLC (aHR=2.498, 95% CI: 1.417 – 4.406, p=0.002). Median VL remained < 400 copies/ml in both arms at 6 weeks, 6 and 24 months postpartum.

- 51 Conclusions: Our findings suggest that programmatic interventions that provide group
- 52 support, community based ART distribution and income-generation activities may contribute
- 53 to retention in PMTCT care, HIV-free survival of children born to women living with HIV,
- and to the elimination of mother to child HIV transmission (MTCT).

INTRODUCTION

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

Prevention of mother-to-child HIV transmission (PMTCT) remains a pillar in the global fight against HIV/AIDS. "Option B+" for PMTCT recommends lifelong triple ART for all pregnant and breastfeeding women living with HIV regardless of immune status. Option B+ also recommends protecting these women's newborns with daily Nevirapine or Zidovudine from birth through 4-6 weeks of age, regardless of the infant feeding method (1). In April 2012, the World Health Organisation (WHO) recommended Option B+ as the PMTCT treatment option which would provide the highest clinical benefits and programmatic advantages for both the care and treatment of mothers living with HIV and perinatal HIV prevention (1). Compared to previous proven PMTCT regimens, Option B+ was easier to deliver and more effective in reducing mother-to-child HIV transmission (MTCT) (2-4). Based on these recommendations, a number of low-income countries including Uganda adopted Option B+ as standard of care with the aim to eliminate MTCT of HIV. Despite this progress and the proven efficacy of Option B+ (5), poor adherence to lifelong ART and low retention in care of pregnant and postpartum women living with HIV has remained an important programmatic challenge to the implementation of Option B+ especially in low resource settings (6-11). A review of studies done between 2000-2020 identified barriers to taking ART among pregnant women that included financial constraints limiting access to food and transport, and side effects of the therapy (12). Additionally, high dropout rates from PMTCT care have been documented after delivery and at two years of follow-up among mothers living with HIV (13-15), suggesting that service integration and linking mothers to routine ART services were important determinants of retention in care. These findings highlighted the critical need for innovative interventions to promote retention in HIV care and adherence to ART for the successful implementation of option B⁺.

In Uganda, adherence counseling by clinic-based midwives trained in counseling and the use of "buddies" as well as family involvement are recommended by the Ministry of Health (MOH) to support maternal ART adherence and retention in care (16). However, there is limited focus on the use of community-based support interventions. Studies in other resource-limited settings have shown better PMTCT intervention adherence with the use of community-based counseling, support groups and home visits (17-20). Additionally, studies in Kenya have demonstrated that peer support from community-based mentor mothers to improve ART adherence and retention in care was well accepted among women living with HIV (21, 22).

Given these challenges, we conducted a randomized controlled trial (RCT) to compare adherence to PMTCT clinic appointments and ART at different time points within 24 months of postpartum follow-up among women started on ART while pregnant and randomized to an enhanced peer group support intervention including community-based drug distribution and income-generating activities called "Friends for Life Circles" (FLCs) versus the MOH standard of care (SOC).

METHODS

We conducted an open-label RCT between 16 May 2016 and May 2020 at Mulago National Referral Hospital and two health centers (HCs III & IV) in Kampala, the capital city of Uganda; and at rural Mityana District Hospital (74 kms northwest of Kampala) as well as five HCs III and IV in Mityana district. Participants were recruited from 16 May 2016 to 12 September 2017 and follow up was completed on 26 May 2020. The selected HCs represent different levels of maternal health care offered in Uganda. The study was implemented and coordinated by the Makerere University–Johns Hopkins University (MUJHU) Research Collaboration based at Mulago Hospital in Kampala.

Enrollment and randomization procedures

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

We enrolled pregnant women living with HIV initiated on PMTCT Option B+ who were: ≥ 18 years old, confirmed pregnant by urine dipstick, confirmed HIV-positive by rapid HIV testing as per National PMTCT Guidelines, being ART-naïve and beginning Option B+ ART within 30 days of enrolment into the study, residing within 20 km of the study clinic, not planning to move out of the clinic catchment area within 2 years, agreeing to be home visited, and providing written informed consent. Pregnant women testing HIV-positive through the routine National PMTCT Program and starting Option B+ were referred to study counselors by the clinic PMTCT counselors for prescreening and scheduled to return to the study clinics for consent procedures within one month of starting once daily Option B+ ART. HIV rapid testing followed the national and WHO algorithms (23) using three sequential antibody rapid tests: Abbott Determine Rapid HIV 1 Test, Abbott Laboratories, USA; Stat Pak Rapid HIV-1 Test, Chembio Diagnostic Systems, USA; and Unigold HIV Rapid Test, Trinity Biotech, Ireland. Eligible and consenting women were then randomized 1:1 irrespective of the study sites to SOC control arm or FLC intervention arm. The randomization list was computer-generated by the data manager based at MUJHU using random-sized block groups that included consecutive intervention numbers with corresponding random intervention assignments. Each pregnant woman was assigned unique participant identification number and authors had no access to information that could identify individual participants during or after data collection After randomization, participants were assessed for socioeconomic status, ARV drug adherence and stigma. A questionnaire addressing participants' experiences with stigmatization and discrimination at family and community levels was administered at baseline, 12 months post-enrolment and at end of study. An additional needs assessment questionnaire

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

was administered to participants enrolled in the FLC arm at enrolment, 1-year post enrolment and every 6 months thereafter until the end of study. This was to assess individuals' achievements and to document challenges related to group activities and participation in income-generating activities (IGAs) and its benefits, skills acquired and training needs. **FLC Intervention and SOC controls** The FLC intervention (hereafter 'FLC') included community-based enhanced peer group support, IGAs and community-based drug distribution. Participants in the FLC arm formed dynamic peer support groups based on women's home addresses documented by Geographical Positioning System (GPS). Groups consisted of 8-10 participants who attended monthly meetings in their communities. Sustainable livelihood study assistants and study counselors participated in and documented FLC group activities. Each FLC group was supported by one peer mother who had similar social background and/or life experiences as FLC participants. During monthly FLC group meetings, study counselors distributed ART and Cotrimoxazole and offered psychosocial support on follow-up clinic visits and drug adherence through individual and group counseling while emphasizing peer support among participants. FLC groups also offered skills building in a variety of IGAs such as goat rearing, bakery, crafts making, liquid soap making, book binding and charcoal briquette making. These were chosen by the participants and implemented as a group or as individuals with the guidance of a study IGA Advisor. All FLC groups were linked to local government bodies for sustainability, registration and access to Community Development Driven grants funded by the District Local Government to support the implementation of livelihood projects for community-based groups. SOC arm participants received counseling from clinic PMTCT counselors and collected their

drug refills on an individual basis from the PMTCT clinics where they were enrolled as per

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

MOH guidelines (16). SOC arm participants participated voluntarily in family support groups whenever available at their respective health facility as recommended by the MOH (16). Follow-up procedures At each study site, all study participants were followed at a dedicated clinic for all scheduled and unscheduled visits and were given transport reimbursement for scheduled study visits. Scheduled visits included a first visit within the initial four weeks post-enrolment, then monthly thereafter until delivery, at delivery, at 6 and 14 weeks postpartum, and quarterly thereafter from 6 months through 24 months postpartum (end of follow-up). At each of these visits, FLC participants were counseled by study counselors on drug adherence and family planning while SOC participants were counseled by PMTCT counselors. Study counselors administered questionnaires on ART adherence, stigma, and socio-economic status to all participants at each scheduled clinic visit. Participants were terminated from the study if they missed four or more consecutive scheduled study visits, withdrew consent, relocated outside study area, or died. **Infant procedures** All infants born to study participants were enrolled in the study and received daily Nevirapine syrup from birth up to 6 weeks of age regardless of the infant feeding method. Infants were tested routinely at 6 weeks of age for HIV by DNA PCR and at 18 months of age by rapid HIV antibody test as part of the National Early Infant HIV Diagnosis Program (23). **Outcomes and measures** The primary outcomes of interest included adherence to PMTCT clinic appointments at 6 weeks, 12 and 24 months postpartum and adherence to Option B+ ART at 6 weeks, and 6 and 24 months postpartum.

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

Complete adherence to visits was defined as having attended the 4 scheduled quarterly visits at the end of each of the first and second years of postpartum follow-up as defined by the MOH (16). Scheduled visits were determined to have been adhered to on the basis of a completed visit within a 3-week window on either side of the scheduled visit date. Retention in care was defined as the proportion of participants who were not terminated from the study prior to the end of follow-up (24 months postpartum). Causes for termination included participant relocation out of the study area, withdrawal from the study, loss to follow-up, miscarriage, referral outside the study facility, and death. The study defined loss to follow-up as not attending 3 consecutive scheduled study visits. Retention in care was calculated as 1 minus the proportion of women terminated for any such reason before the end of follow-up. As a second primary outcome, we compared maternal ART adherence using self-report at 6 weeks and 6 and 24 months postpartum among all study participants. We validated selfreports by comparing VL measurements for all participants at 6 weeks, 6 and 24 months postpartum. All participants were asked to self-assess the number of complete ART doses they missed in the past three days. Self-reported ART adherence was then calculated as 1 minus the proportion of self-reported doses missed in the past 3 days. Laboratory measures of ARV adherence were used to validate self-reports using viral suppression below 400 copies/mL. At the time of writing the study protocol, this limit was considered as viral suppression by Uganda MOH (16). VL measurements were performed at the Infectious Diseases Institute (IDI) Core Laboratory, Kampala, Uganda, a central laboratory certified by the American College of Pathologists. Nucleic acids were extracted and tested for HIV-1 RNA using the COBAS® AmpliPrep/ COBAS® TaqMan® HIV-1 Test procedure

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

following the manufacturer's instructions (Roche Molecular Systems, Inc., Branchburg, NJ, 08876 USA) (25). Virological failure was defined as median viral load persistently above 1000 copies/ml for two consecutive viral load measurements within a three-month interval after at least 6 months of initiating ART. The final drug adherence variable at each time point was dichotomized as 'not adhering' if viral load was ≥400 copies/ml irrespective of the level of self-reported adherence, or as 'adhering' if self-reported adherence in the last 3 days was ≥95% and viral load was <400 copies /ml. Lastly, the HIV status and the HIV-free survival of children born to study participants were assessed at their 6 week and 18-month postpartum visits as per the National PMTCT program recommendation and practice. **Statistical Analyses** We estimated a target sample size of at least 270 women living with HIV needed to be enrolled in each of the study arms to provide 90% power at 5% significance level to detect a difference of 15% or more in adherence to visits and drugs or in virological suppression between the intervention and control arms. Follow-up time was calculated in person-years, with each participant contributing time in years from enrolment to censoring at the date when a participant was lost to follow-up, died or reached the end of study. We compared participants' baseline characteristics in the FLC and SOC arms by testing for differences in proportions using Fisher's exact p-values. Maternal adherence to at least 4 scheduled PMTCT clinic appointments at the end of each year of postpartum follow-up, adherence to ART and retention in care, as well as the HIV status of children were also summarized using proportions and chi-square p-values. We used the Wilcoxon-Breslow-

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

Gehan test to assess the difference in HIV-free survival of participants' children between the FLC and SOC arms. Log rank and Chi-Square p-values were used to test the equality of Kaplan-Meier survival probabilities and hazard rates for failure to retain in care for any reason by study arm. Cox Proportional Hazard regression model adjusted for unbalanced baseline variables was used to estimate the hazard rate ratio of failing to retain participants in care with 95% confidence intervals between the FLC and the SOC arms. Ethical and regulatory considerations The study was approved by Uganda's National Council of Science and Technology (UNCST), the Joint Clinical Research Centre (JCRC) Institutional Review Board (IRB), as well as the IRBs of Johns Hopkins University (JHU) and the University of California San Francisco (UCSF). Written informed consent was obtained from all study participants by study counselors in the presence of an impartial witness before enrolment in the study. **RESULTS** Between May 2016 and September 2017, a total 1192 HIV-positive pregnant women were assessed for study eligibility. Of these, 45 % (540/1192) were found eligible and randomized 1:1 to either the intervention or the control arm until each arm accrued 270 participants across all study sites (Fig 1). Figure 1 – Trial Profile **Baseline demographic characteristics** Table 1 provides the number of participants, clinic visits made, and person-years of follow-up by baseline socio-demographic characteristics of the study population stratified by study arm. These results show that despite randomization, there were significant differences between the

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

two study arms in participants' educational level, gravidity, HIV status disclosure to partner and monthly income. Table 1. Baseline socio-demographic characteristics of study population (N=540) Adherence to PMTCT clinic appointments There was no statistically significant difference between the intervention and control arms in the number of women who started or completed their postpartum visits at 6 weeks postpartum or in the first or second year of follow-up (Table 2). **Table 2. Adherence to PMTCT clinic appointments Retention in care** Overall, retention in care was high across both study arms with 83.0% of all participants remaining in care at the end of follow-up (Table 3). Significantly, more women were retained in care at the end of follow-up in the FLC arm (86.7%) compared to the SOC arm (79.3%, p= 0.0221). Also, more women were terminated before the end of follow-up due to relocation in the SOC arm (n=27, 10.0%) compared to the FLC arm (n=12, 4.4%). Table 3. Retention in care by study arm at the end of study There was a significant difference between the Kaplan-Meier survival functions for failure to remain in care until the end of study (24 months postpartum visit) between the control and intervention arms (Wilcoxon-Breslow test for equality of survivor functions $Chi^2(1) = 11.94$, p-value = 0.0005) (Figure 2). Overall, the estimated proportion of participants retained in care was high, with 87.0% of all participants remaining in care until the end of the study.

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

Figure 2. Kaplan-Meier survival curves for retention in care up to 24 months postpartum. Adherence to ART Table 4 shows that participants self-reported optimal adherence to taking >95% of their ART medication in the last 3 days at their 6 weeks, 6 and 24 months postpartum visits. There was no statistically significant difference in optimal adherence to ART between the arms. The median viral loads of participants at each of these time points were <100 copies/ml with no statistically significant differences between the two arms. Table 4. Adherence to Option B+ ART by study arm **Predictors of retention in care** Cox-proportional hazard regression models were used to assess the effect measure of intervention on being retained in care. All baseline variables with p<0.1 at the univariate level were included in the multivariate model and using a backward elimination method, only those variables with p<0.05 were kept in the final model. Table 5: Multivariate Cox proportional hazard model for failure to remain in care Table 5 shows that the rate of dropout from care was 2.5 times greater among participants randomized to the SOC arm versus the FLC arm (aHR=2.498, 95% CI: 1.417 - 4.406, p=0.002). Participants enrolled from rural health facilities and those aged 15-24 years were also significantly less likely to be retained in care compared to their urban (p=0.021) or their

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

older counterparts (p=0.035) respectively. Educational level, gravidity, disclosure status and income were not significant predictors of retention in care and were not included for analysis in the final model. HIV-free survival of children Of 492 women with a visit at 18 months postpartum, 8 of their 431 (1.9%) tested infants tested positive for HIV. Most (7/8) of these infants had tested positive to HIV by the 6th week postpartum visit. The proportion of HIV-positive children born to mothers enrolled in the FLC arm (1.4%) was not significantly different from that observed in the SOC arm (2.4%) (p=0.472). By the 18-month postpartum visit, the HIV-free survival of children born to mothers in the FLC arm was 93.8% [95% CI: 89.9 – 96.2] compared to 83.0% [95% CI: 75.9 – 87.7] among children born to mothers in the SOC arm. The difference between the two arms was significant (p=0.0031). **Discussion** In this RCT, we found that there was no statistical difference through 24 months of postpartum follow-up in adherence to PMTCT clinic visits or ART among pregnant and postpartum women started on Option B+ ART during pregnancy and randomized to the FLC intervention or the MOH SOC services. We however found that women in the FLC arm were statistically significantly more likely to have remained in PMTCT care through 2 years postpartum compared to the SOC arm. This is comparable to the study by Masereka et al, which found that 87.9% of women were retained in care after being initiated on Option B+ in Uganda (26). Our data is also consistent

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

with a study from Malawi which found that at 24 months after initiation of Option B+ ART, retention in the peer group models was 80% and 83% in the facility-based and communitybased arms respectively, compared with 60% in the standard of care arm (17). This may explain the absence of a statistically significant difference between the intervention and control arm when it came to adherence to PMTCT clinic appointments. In both arms of this RCT, 87% or more participants self-reported optimal adherence to taking their ART at 6 weeks, 6- and 24-months postpartum and the median viral load levels of participants were under 100 copies/ml at each of these time points with no significant difference between the FLC and SOC arms. We did not find fluctuations in longitudinal adherence during the postpartum period. A systematic review by Wubneh et al in Ethiopia found that the pooled estimate of good adherence to Option B+ ART among 1852 pregnant and lactating women was 84% (27), which is comparable to our finding. Our finding is also consistent with a cohort study done in Malawi that found 90%-100% adherence to ART among women on Option B+ observed from 4 to 21 months postpartum (28). That study used pharmacy records to measure adherence as opposed to self-reports and VL validation which may limit comparisons with our study. Although we found high self-reported adherence to ART that corroborated with low median viral loads, we did not find significant differences in these outcomes between the FLC and SOC arms at any follow-up time points. The close correlation between these outcomes echo the findings of a study among 452 women on PMTCT care and treatment in South Africa where it was found that a raised viral load was consistently associated with lower median adherence scores (29). However, the lack of a more distinct outcome from the FLC intervention may result from a study effect or still a 'contamination' between the FLC and SOC arms among both study staff and participants in the study facilities (30).

Few children were found infected with HIV postnatally and most of them were likely infected *in utero* or at birth given the timing of their positive test result. However, our finding that HIV-free survival of children born to mothers in the FLC arm was significantly higher than those in the SOC arm is noteworthy as it implies that more children died of non-HIV causes in the latter arm. Many factors may have accounted for this outcome but peer support, less variation in drug adherence and increased economic security (through IGAs) and thus the ability of mothers to better feed and care for their babies all are plausible explanations supported by an ample literature (31-37).

Limitations

Our study's main limitation is that our RCT was individually and not cluster randomized, which may have resulted in cross-contamination between the FLC and the SOC arms in the same clinics over the long-term follow-up period. Contamination could have also occurred when study staff attended to both FLC and SOC participants at the same clinic. Additionally, all study participants were given transport reimbursement for their study visits which may have positively influenced adherence to study visits. Lastly, the feasibility of our intervention would depend on its cost and cost-effectiveness, which we did not assess.

Conclusions

Our study found that the FLC intervention significantly increased retention in care and HIV-free survival of children of pregnant mothers living with HIV through 24 months postpartum. These findings are encouraging and suggest that programmatic interventions such as the FLC may contribute to the goal of eliminating MTCT of HIV in Uganda. We recommend scaling up peer group support, community drug distribution and income-generation intervention strategies in the context of PMTCT.

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

Conflict of Interest Statement The authors declare that they have no conflict interests. **Authors' contributions** JNM, IL, RK, JH, CN, ZN, MN, MGF and PM contributed to the conception and design of the study. AA and GG wrote the original draft. GR contributed to data curation. SM carried out statistical analysis. AA, GG, JH, PW, SM, RK, SM, CN and PM reviewed and edited the manuscript. All authors approved the final manuscript. Acknowledgements We would like to thank the FLC for Option B+ study team who were vital in the collection of this data and the study participants without whom this study would not have been possible. **Funding:** The Friends for Life Circles for Option B+ study which was funded by NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) grant # IR01HD080476-01.

References

379

401

World Health Organization. (2012). Programmatic update: use of antiretroviral drugs for 380 treating pregnant women and preventing HIV infection in infants: Executive Summary. 381 World Health Organization. https://apps.who.int/iris/handle/10665/70892 382 2. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for 383 treating and preventing HIV infection: recommendations for a public health approach. 384 World Health Organization; 2016. 385 386 3. DiCarlo, A.L., Gachuhi, A.B., Mthethwa-Hleta, S., Shongwe, S., Hlophe, T., Peters, Z.J., Zerbe, A., Myer, L., Langwenya, N., Okello, V. and Sahabo, R., 2019. Healthcare 387 worker experiences with Option B+ for prevention of mother-to-child HIV transmission 388 in eSwatini: findings from a two-year follow-up study. BMC health services 389 research, 19(1), pp.1-12 PMID: 30940149 PMCID: PMC6444445 390 391 4. Muyunda, B., Musonda, P., Mee, P., Todd, J. and Michelo, C., 2020. Effectiveness of lifelong ART (Option B+) in the prevention of mother-to-child transmission of HIV 392 programme in Zambia: observations based on routinely collected health data. Frontiers in 393 Public Health, p.401. PMID: 32010656 PMCID: PMC6978742 394 5. Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al. Benefits and 395 risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016 396 Nov;375(18):1726–37. PMID: 27806243 PMCID: PMC5214343 397 6. Haas AD, Tenthani L, Msukwa MT, Tal K, Jahn A, Gadabu OJ, Spoerri A, 398 Chimbwandira F, van Oosterhout JJ, Keiser O. Retention in care during the first 3 years 399 of antiretroviral therapy for women in Malawi's option B+ programme: an observational 400

cohort study. The Lancet HIV. 2016 Apr 1;3(4):e175-82.

7. Atanga PN, Ndetan HT, Fon PN, Meriki HD, Muffih TP, Achidi EA, Hoelscher M, 402 Kroidl A. Using a composite adherence tool to assess ART response and risk factors of 403 poor adherence in pregnant and breastfeeding HIV-positive Cameroonian women at 6 404 and 12 months after initiating option B+. BMC pregnancy and childbirth. 2018 405 Dec;18(1):1-0. 406 Gamell A, Luwanda LB, Kalinjuma AV, Samson L, Ntamatungiro AJ, Weisser M, et al. 407 Prevention of mother-to-child transmission of HIV Option B+ cascade in rural Tanzania: 408 The One Stop Clinic model. Charpentier C, editor. PLoS One. 2017 Jul;12(7):e0181096. 409 PMID: 28704472 PMCID: PMC5507522 410 9. Ritchie LM, van Lettow M, Pham B, Straus SE, Hosseinipour MC, Rosenberg NE, Phiri 411 S. Landes M. Cataldo F. What interventions are effective in improving uptake and 412 413 retention of HIV-positive pregnant and breastfeeding women and their infants in prevention of mother to child transmission care programmes in low-income and middle-414 income countries? A systematic review and meta-analysis. BMJ open. 2019 Jul 415 1;9(7):e024907. 416 417 10. Mukosha M, Chiyesu G, Vwalika B. Adherence to antiretroviral therapy among HIV infected pregnant women in public health sectors: a pilot of Chilenje level one Hospital 418 Lusaka, Zambia. The Pan African Medical journal. 2020;35. 419 420 11. Mukose AD, Bastiaens H, Makumbi F, Buregyeya E, Naigino R, Musinguzi J, Van Geertruyden JP, Wanyenze RK. What influences uptake and early adherence to Option B+ (lifelong 421 antiretroviral therapy among HIV positive pregnant and breastfeeding women) in Central 422 Uganda? A mixed methods study. PloS one. 2021 May 5;16(5):e0251181. 423 12. Mwamba Kalungwe, Scovia Nalugo Mbalinda, Thamary Karonga, Niza Rean Simwanza, 424 Catherine M. Mumba Mtambo, Mathew Nyashanu. Exploring barriers to antiretroviral

425

therapy adherence among pregnant women: A scoping literature review. Gyn & 426 Obstetrics 2022, 159(2):343-350. https://doi.org/10.1002/ijgo.14130 427 428 13. Knettel BA, Cichowitz C, Ngocho JS, Knippler ET, Chumba LN, Mmbaga BT, et al. Retention in HIV Care during Pregnancy and the Postpartum Period in the Option B+ 429 Era: Systematic Review and Meta-Analysis of Studies in Africa. Vol. 77, Journal of 430 431 Acquired Immune Deficiency Syndromes. Lippincott Williams and Wilkins; 2018. p. 427-38. PMID: 29287029 PMCID: PMC5844830 432 433 14. Kiragu K, Collins L, Von Zinkernagel D, Mushavi A. Integrating PMTCT into maternal, newborn, and child health and related services: Experiences from the global plan priority 434 countries. J Acquir Immune Defic Syndr. 2017;75:S36-42. PMID: 28398995 435 436 15. Mushamiri I, Belai W, Sacks E, Genberg B, Gupta S, Perry HB. Evidence on the effectiveness of community-based primary health care in improving HIV/AIDS 437 outcomes for mothers and children in low- and middle-income countries: Findings from 438 a systematic review. J Glob Health. 2021 Jul 10;11:11001. doi: 10.7189/jogh.11.11001. 439 PMID: 34327001; PMCID: PMC8284540 440 441 16. Ministry of Health- Uganda. Consolidated Guidelines on the prevention and treatment of HIV and AIDS in Uganda. 2018; (September):327 442 17. Rosenberg NE, van Lettow M, Tweya H, Kapito-Tembo A, Bourdon CM, Cataldo F, 443 Chiwaula L, Sampathkumar V, Trapence C, Kayoyo V, Kasende F. Improving PMTCT 444 uptake and retention services through novel approaches in peer-based family-supported 445 446 care in the clinic and community: a three-arm cluster randomized trial (PURE Malawi). Journal of acquired immune deficiency syndromes. 2014 Nov 1;67(0 2):S114. 447 18. Phiri S, Tweya H, Van Lettow M, Rosenberg NE, Trapence C, Kapito-Tembo A, et al. 448 Impact of facility- and community-based peer support models on maternal uptake and 449

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

and retention in Malawi's option B+ HIV prevention of mother-to-child transmission program: A 3-arm cluster randomized controlled trial (PURE Malawi). J Acquir Immune Defic Syndr. 2017;75:S140-8. PMID: 28498183 19. Lyatuu GW, Naburi H, Mwashemele S, Lyaruu P, Urrio R, Simba B, Philipo E, Kibao A, Kajoka D, Sando D, Orsini N. Effect of peer-mother interactive programme on prevention of mother-to-child HIV transmission outcomes among pregnant women on anti-retroviral treatment in routine healthcare in Dar es Salaam, Tanzania. PLOS Global Public Health. 2022 Mar 9;2(3):e0000256. 20. Pugh LE, Roberts JS, Viswasam N, Hahn E, Ryan S, Turpin G, Lyons CE, Baral S, Hansoti B. SYSTEMATIC REVIEW OF INTERVENTIONS AIMED AT IMPROVING HIV ADHERENCE TO CARE IN LOW-AND MIDDLE-INCOME COUNTRIES. Journal of Infection and Public Health. 2022 Aug 28. 21. Helova A, Onono M, Abuogi LL, Hampanda K, Owuor K, Odwar T, Krishna S. Odhiambo G, Odeny T, Turan JM. Experiences, perceptions and potential impact of community-based mentor mothers supporting pregnant and postpartum women with HIV in Kenya: a mixed-methods study. Journal of the International AIDS Society. 2021 Nov;24(11):e25843. 22. Wanga I, Helova A, Abuogi LL, Bukusi EA, Nalwa W, Akama E, Odeny TA, Turan JM, Onono M. Acceptability of community-based mentor mothers to support HIV-positive pregnant women on antiretroviral treatment in western Kenya: a qualitative study. BMC pregnancy and childbirth. 2019 Dec;19(1):1-2. 23. Ministry of Health- Uganda. National HIV Testing Services Policy and Implementation Guidelines

24. Omonaiye O, Nicholson P, Kusljic S, Manias E. A meta-analysis of effectiveness of 474 interventions to improve adherence in pregnant women receiving antiretroviral therapy in 475 sub-Saharan Africa. International Journal of Infectious Diseases. 2018 Sep 1;74:71-82. 476 26. . 477 25. Roche Diagnostics. COBAS ® AmpliPrep/COBAS ® TaqMan ® HIV-1 Test package 478 insert. :1-36. 479 26. Masereka EM, Ngabirano TD, Osingada CP, Wiltshire CS, Castelnuovo B, Kiragga AN. 480 481 Increasing retention of HIV positive pregnant and breastfeeding mothers on option-b plus by upgrading and providing full time HIV services at a lower health facility in rural 482 Uganda. BMC public health. 2019 Dec;19(1):1-6. 483 27. Wubneh CA, Mekonnen BD, Delelegn MW, Atalell KA. Adherence to option B+ and its 484 association with disclosure status and counseling among HIV-positive pregnant and 485 486 lactating women in Ethiopia: systematic review and meta-analysis. Public Health. 2022 Oct 1;211:105-13. 487 28. Haas AD, Msukwa MT, Egger M, Tenthani L, Tweya H, Jahn A, Gadabu OJ, Tal K, 488 Salazar-Vizcaya L, Estill J, Spoerri A. Adherence to antiretroviral therapy during and 489 after pregnancy: cohort study on women receiving care in Malawi's option B+ program. 490 Clinical infectious diseases. 2016 Nov 1;63(9):1227-35. 491 29. Phillips T, Brittain K, Mellins CA, Zerbe A, Remien RH, Abrams EJ, Myer L, Wilson 492 IB. A Self-Reported Adherence Measure to Screen for Elevated HIV Viral Load in 493

Pregnant and Postpartum Women on Antiretroviral Therapy. AIDS Behav. 2017

Feb;21(2):450-461. PMID: 27278548; PMCID: PMC5145763

494

495

23

30. Magill N, Knight R, McCrone P, Ismail K, Landau S. A scoping review of the problems 496 and solutions associated with contamination in trials of complex interventions in mental 497 health. BMC medical research methodology. 2019 Dec;19(1):1-3. 498 31. Berg RC, Page S, Øgård-Repål A. The effectiveness of peer-support for people living 499 with HIV: A systematic review and meta-analysis. PLoS One. 2021 Jun 500 501 17;16(6):e0252623. 32. Yotebieng M, Thirumurthy H, Moracco KE, Edmonds A, Tabala M, Kawende B, Wenzi 502 LK, Okitolonda EW, Behets F. Conditional cash transfers to increase retention in 503 PMTCT care, antiretroviral adherence, and postpartum virological suppression: a 504 randomized controlled trial. Journal of acquired immune deficiency syndromes (1999). 505 506 2016 Aug 1;72(Suppl 2):S124. 33. Liu JX, Shen J, Wilson N, Janumpalli S, Stadler P, Padian N. Conditional cash transfers 507 to prevent mother-to-child transmission in low facility-delivery settings: evidence from a 508 randomised controlled trial in Nigeria. BMC pregnancy and childbirth. 2019 509 Dec;19(1):1-2. 510 511 34. Camlin CS, Marson K, Ndyabakira A, Getahun M, Emperador D, Byamukama A, Kwarisiima D, Thirumurthy H, Chamie G. Understanding the role of incentives for 512 achieving and sustaining viral suppression: A qualitative sub-study of a financial 513 incentives trial in Uganda. Plos one. 2022 Jun 24;17(6):e0270180. 514 515 35. Imbaya CL, Odhiambo-Otieno GW, Okello-Agina BM. Adherence levels to antenatal 516 regimens of NVP and AZT among HIV+ women receiving PMTCT treatment at Pumwani Maternity Hospital in Nairobi, Kenya. AIDS 2008 - XVII International AIDS 517

Conference: Abstract no MOPE05192008

518

36. Chime OH, Arinze-Onyia SU, Obionu CN. Do peer support groups have an effect on medication adherence? A study among people living with HIV/AIDS in Enugu State, Nigeria. Proc Singapore Health Conference. 2018;27(4):256–64.
37. Fahey CA, Njau PF, Katabaro E, Mfaume RS, Ulenga N, Mwenda N, Bradshaw PT, Dow WH, Padian NS, Jewell NP, McCoy SI. Financial incentives to promote retention in care and viral suppression in adults with HIV initiating antiretroviral therapy in Tanzania: a three-arm randomised controlled trial. The Lancet HIV. 2020 Nov 1;7(11):e762-71.

Figure 2. Kaplan-Meier survival curves for retention in care over time up to 24 months postpartum.




Table 2. Adherence to PMTCT clinic appointments

	Adherence to PMTCT clinic appointments Primary outcomes measure (A)	At 6 Weeks Postpartum visit		Number at least 4 qua visits in the postpartur measured Months Po visit	arterly le 1st year n at the 12 ostpartum	Number attended at least 4 quarterly visits in the 2 nd year postpartum measured at the 24 Months Postpartum visit	
		FLC ARM	SOC ARM	FLC SOC ARM ARM		FLC ARM	SOC ARM
medRxiv preprint	dei: -\www.\/dei:->\w\48.1484\/8888.04.15.28888465: !his version	posted April 17, 202	3. The copyright hol	Her for this preprint			
(which was no	doi: https://doi.org/10.1101/2020.04.15.20200405; this version t dertified by peer jeyjevr) is the author/funder, who has grant this made available under a CC-BY 4.0 Ir	ed medfixiva licens ternational license . (89.6%)	e toodsplayzine grer (85.6%)	ringingerpending (85.1%)	197/247 (79.8%)	187/245 (76.3%)	168/224 (75.0%)
	Includes all women who started the time window of interest (6 weeks postpartum, the first or the second year of postpartum follow-up)						
	Fisher's Exact p-values	P=0	.192	P=0	.129	P=0.748	
	As treated analysis:	242/262 (92.4%)	231/247 (93.5%)	223/245 (91.0%)	197/224 (87.9%)	187/229 (81.7%)	168/207 (81.2%)
	Includes all women who completed the time window of interest (6 weeks postpartum, the first or the second year of postpartum follow-up)						
	Fisher's Exact p-values	P=0	.730	P=0	.294	P=0	.903

PP = postpartum

^a Women who attended \geq 4 quarterly visits in the 1st year PP

^b Women who attended > 4 quarterly visits in the 2nd year PP

Table 3. Retention in care by study arm at the end of study

	Study Arm, n (%)						
Follow-up status at end of study	FLC=270 n (column %)	SOC=270 n (column %)	Total=540 n (column %)				
Terminated before end of follow-up	36 (13.3%)	56 (20.7%)	92 (17.0%)				
Terminated due to relocation	12 (4.4%)	27 (10.0%)	39 (7.2%)				
Lost to follow-up	3 (1.1%)	3 (1.1%)	6 (1.1%)				
Withdrawn from study	15 (5.5%)	17 (6.3%)	32 (5.9%)				
Termination due to death	1 (0.4%)	6 (2.2%)	7 (1.3%)				
Other - Miscarriage/Referred/No time	2 (0.7%)	3 (1.1%)	5 (0.9%)				
medRxiv preprint doi: https://doi.org/10.1101/2023.04.15.23288495; this version posted April 17 (which was not certified by paer review) is the author/funder, who has granted medRxiv a It is made available under a CC-BY 4.0 International lice	, 2023. The copyright holder for thi icense to display the preprint in pense .	s preprint petuity. 0 (0.0%)	3 (0.6%)				
Missed last 24 months PP visit	0 (0.0%)	6 (2.2%)	6 (1.1%)				
Completed follow-up	234 (86.7%)	208 (77.0%)	442 (81.9%)				
Retention in care	1 - (36/270) (86.7%)	1 - (56/270) (79.3%)	1 - (92/540) (83.0%)				
p-value [†]	0.02	21					

n = Number of individuals; PP = Postpartum

[†] Chi-square (1) = 8.453

Table 4. Adherence to Option B+ ART by study arm

Adherence to Option B+ ART		6 weeks p	ostpartum	6 months p	oostpartum	24 months postpartum		
Self-repo	reported FLC		SOC	FLC	SOC	FLC	SOC	
Proportio	on of doses	11/242	9/232	29/225 34/216		22/223	20/200	
missed in	n past 3 days*	(4.6%)	(3.9%)	(12.9%)	(15.7%)	(9.9%)	(10.0%)	
Adheren	therence to taking ARV 1 - 4.6% 1 - 3.9% or option B+ ** (95.4%) (96.1%)		1 - 3.9%	1 – 12.9%	1 – 15.7%	1 – 9.9%	1 – 10.0% (90.0%)	
for option			(96.1%)	(87.1%)	(84.3%)	(90.1%)		
p-values	p-values		p=0.718		.122	p=0.644		
(which was not certi	fied by peer (eview) is the author/f It is made available	inder, who has granted med inder a Co EV 0 Internation	Rxiv a license to display the nal licens.	e preprint in perpetuity.	SOC	FLC	SOC	
Median l	og ₁₀ VL (IQR) †	1.80	1.86	1.64	1.52	1.30	1.30	
		(1.30-2.61)	(1.34-2.78)	(1.30-2.66)	(1.30-3.79)	(1.30-2.77)	(1.30-2.83)	
Median o	copies/mL (IQR) †	63 cp/ml	72 cp/ml	44 cp/ml	33 cp/ml	20 cp/ml	20 cp/ml	
		(20-407)	(22-603)	(20-457)	(20-6,166)	(20-589)	(20-676)	

^{*} No. of women with sub-optimal adherence in the past 3 days prior to clinic visit / Total number of women visiting the clinic and responding to the past 3 days adherence questions at each visit of interest (6 weeks pp, 6 months and 24 months pp). These results have accounted for the validation of self-reported adherence using viral load measures (Self-reported adherence with a viral load <400 copies/ml was classified as Adherent and self-reported adherence with a viral load ≥400 copies/ml was classified as non-adherent)

^{** 1} minus the proportion of women self-reported as sub-optimally taking their medication in the past 3 days

[†] At 6 weeks postpartum, we used VL test results for samples taken at delivery. Samples taken at 6 weeks were stored for analysis at a later time

Table 5: Multi-variable Cox Proportional Hazard model for failure to remain in care

Variables	Variables		Hazard Ratio (HR)	[95% Conf. Interval]	p-value	
Study arm	Study arm FLC		1.000			
	SOC	270	2.498	1.417 - 4.406	0.002	
Urban status	Urban	401	1.000			
	Rural	139	0.412	0.195 - 0.868	0.020	
Age	15-24 years	259	1.000			
	25-34 years	241	0.546	0.311 - 0.959	0.035	
	35+ years	40	0.585	0.179 - 1.906	0.373	
dRxiv preprint doi: https://doi.o.g/(3.1101/20) which was not certified by peer review) is	23.04.15.232288493; this versi he author/funder, who has gr	on posted April 17 anted medRxiv a	2023. The copyright halder for this prepr cense to display the preprint in perpetuity	rint /.		
It is made	e available under a CC-BY 4. Ganda	International lice	0.625	0.374 - 1.044	0.073	

Trial Profile




Table 1. Baseline socio-demographic characteristics of study population (N=540)

	Intervention				Control				
		(FLC A	rm)		(SOC Arm)				
Socio-demographic	Person	Person-years		Total no. of		Person-years		Total no. of	
characteristics at baseline	of follo	w-up	women	women in		v-up	women in		
	[PYFU] for	FLC Arm		[PYFU] for		SOC Arm		
	ALL vi	isits			ALL visits				
xiv preprint doi: https://doi.org/10.1101/2023.04.15.23288499ich was not certified by peer review) is the author/funder, It is made available under a	who has grante	d medRxiv a lic	ense to displa	col yright holder y the preprin	Visits for this preprint t in perpetuity.	PYF U	N	col %	p-value
Enrolment Sites									
Kampala-Urban	2455	392.9	200	74.1	2271	354.1	201	74.4	
Mityana-Rural	907	144.5	70	25.9	912	142.8	69	25.6	0.922
Marital Status									
Married/Co-habiting	2607	418.2	209	77.4	2565	399.0	217	80.4	0.655
Never Married	502	77.4	40	14.8	389	61.1	33	12.2	
Separated/Divorced/	253	41.8	21	7.8	229	36.8	20	7.4	
Widowed									
Age									
18-24 years	1415	222.9	116	43.0	1659	257.0	143	53.0	0.068
25-34 years	1654	267.7	130	48.2	1318	206.5	111	41.1	
35+ years	293	46.8	24	8.9	286	33.3	16	5.9	
Educational level									
Tertiary	194	30.9	16	5.9	116	17.9	9	3.3	0.021*
Secondary	1429	227.3	113	41.9	1810	282.4	145	53.7	
Primary	1611	260.2	131	48.5	1140	176.8	103	38.2	
No education	128	18.9	10	3.7	117	19.7	13	4.8	
Religion									
Catholic	1185	188.0	93	34.4	1100	169.8	93	34.4	0.615
Protestant	858	139.8	69	25.6	724	115.4	57	21.1	
Moslem	676	106.0	56	20.7	688	110.4	60	22.2	
SDA/Pentecostal/others	643	103.6	52	19.3	671	101.3	60	22.2	
Tribe									
Non-Ganda	1495	240.7	123	45.6	1292	202.0	116	43.0	0.543
Ganda	1867	296.6	147	54.4	1891	294.9	154	57.0	

Gravidity									
1	613	96.1	51	18.9	630	96.6	54	20.0	0.016*
2	663	106.2	54	20.0	1011	159.7	84	31.1	
3	943	151.1	75	27.8	684	106.9	60	22.2	
4+	1143	184.0	90	33.3	858	133.7	72	26.7	
Disclosure to partner									
Yes	1270	200.5	100	37.0	1396	214.6	118	43.7	0.040*
No	2036	328.1	165	61.1	1640	259.3	140	51.9	
No partner	56	8.8	5	1.9	147	23.0	12	4.4	
medRxiv preprint doi: https://doi.org/10.1101/2023.04.15.23288495 (which was not certified by peer review) is the author/funder, It is made available under a	; this version po	osted April 17, 2	023. The cop	yright holder	for this preprin	t			
(which was not certified by peer review) is the author/funder, it is made available under a	vno nas grante CC-BY 4,0 Inte	a medikxiv a iic ernationa) licens	e . 106	39.3	1 1 79	186.6	97	35.9	0.423
No	2029	324.7	164	60.7	2004	310.3	173	64.1	
Monthly Income (USD)*									
1.35-40.5	591	94.2	46	17.1	772	121.2	65	24.1	0.046*
>40.5-135.1	946	149.5	75	27.8	627	96.5	51	18.9	
>135.1	602	99.0	48	17.8	589	90.4	47	17.4	
Don't know	1223	194.7	101	37.4	1195	188.8	107	39.6	
TOTAL No. of	3362	538.4	270	50.0	3183	497.2	270	50.0	
Participants									
TOTAL No. of All visits			3362	51.4			3183	48.6	
No. of Scheduled PP visits			2017	83.0			1854	76.3	

Legend: PP = postpartum; * significant difference (p<0.05)

PYFU= Person Years of Follow Up. Follow-up time was calculated in person-years, with each participant contributing time in years from enrolment to censoring at either: the date of death, or the date loss to follow-up was reported, or end of follow-up date (24-month postpartum visit)

^{† 1} USD =3,650 UG Shillings (UGX) at the time of enrolment